NewLink to review IDO blocker program following Incyte failure

9 April 2018
newlink-large

Shares in NewLink Genetics (Nasdaq: NLNK) plunged on Friday as the firm announced a review of its clinical programs.

The announcement followed shortly after Incyte (Nasdaq: INCY) revealed the failure of its ECHO-301 melanoma trial, wiping billions from the value of the company. Incyte has been evaluating the IDO pathway inhibitor epacadostat in combination with Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab).

NewLink’s IDO blocker indoximod is being developed in several indications, and the firm says it has a differentiated mechanism of action which could prove successful.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical